The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new products to market, the rewards can be just as substantial. Achieving approval for a new pharmaceutical treatment is something of a ‘Holy Grail’ in the industry.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yet, approval alone does not guarantee commercial success. The real upside emerges when a company can successfully launch a drug, drive physician and patient adoption, and capture a meaningful share of what can sometimes become a multi-billion-dollar market.
Citi analyst Eric Joseph, a long-time expert on the biotech sector, likes the current risk/reward profile in mid-sized biotech stocks, as he believes this segment offers compelling opportunities to develop first- or best-in-class drugs aimed at high unmet medical needs.
“Against the trailing 12+ month backdrop of generally impressive launch execution, upside recognition of clinical wins, healthy M&A activity within the category, as well as a calmer US regulatory and drug pricing backdrop, we hold a positive outlook on the broader commercial SMid Biotech, which posits an attractive mix of validating clinical readouts, pipeline diversification, and opportunities for margin expansion over foreseeable horizon,” Joseph noted.
